| ￥4500 | |
| Z05782-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 0.05EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | CHO | ||||
| Theoretical Molecular Weight | 27.3 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 38-42 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | The R-spondins are members of a superfamily of thrombospondin type 1 repeat (TSR-1)-containing proteins. The prototype member (discovered in 1971) was isolated from platelets that had been stimulated with thrombin, and was therefore designated 'thrombin-sensitive protein. |
| Synonyms | R-spondin-1; RSPO1; CRISTIN3; FLJ40906; RP11-566C13.1; RSPO; R-Spondin1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
